# Legit Sermorelin — An honest notebook on GHRH(1-29), the FDA record, and 503A compounding > A study-notebook reading of the sermorelin literature: what it is, what it was approved for, why it left the market, and where it sits in compounding today. Research context only. Sermorelin was twice FDA-approved, withdrawn for business reasons in 2008, and lives today in Section 503A compounding. This notebook walks the evidence, line by line. ## The short version Sermorelin is a 29-amino-acid lab-made copy of the first part of a natural brain signal called GHRH — growth hormone-releasing hormone — which tells the pituitary gland to make and release the body's own growth hormone. It does not contain growth hormone itself. What makes sermorelin unusual among research peptides is that it has a real FDA history: it was twice approved (as a diagnostic agent in 1990 and as a treatment for children with growth-hormone deficiency in 1997), withdrawn from the US market in 2008 for commercial reasons, and is now compounded by licensed pharmacies under a federal regulatory category called Section 503A [5][6]. It is not currently an FDA-approved drug product. The published human evidence is focused on children with diagnosed growth-hormone deficiency and on older adults whose natural GH levels have declined with age. People also report sleep, energy, and body-composition changes — those are community signals, not settled trial outcomes. [What people report](/effects) has its own page, kept clearly separate from what the studies measured. ## What sermorelin actually is Start with the molecule, because almost every confusion about sermorelin clears up once the structure is on the page. Sermorelin is a synthetic 29-amino-acid peptide — the first 29 residues of human growth hormone-releasing hormone (GHRH), the shortest fragment that keeps the parent hormone's full bioactivity [1]. The names you will see in the literature — GHRH(1-29), GRF(1-29), Growth Hormone-Releasing Factor (1-29) amide, sermorelin acetate — all refer to the same chain [1]. Its job inside the body is small and specific. Sermorelin binds the GHRH receptor (a Gs-coupled receptor on the anterior pituitary's somatotroph cells), raises intracellular cAMP, and prompts the pituitary to transcribe and release its own growth hormone in a pulse [1][8]. Because the pituitary remains the gatekeeper, normal negative feedback from somatostatin and circulating IGF-1 stays intact — which is why intermittent (nightly) dosing in the research literature does not cause the rapid loss of response that continuous GHRH infusion does [9]. It is helpful to hold two facts together from the start. First: sermorelin asks the pituitary to release growth hormone; it is not itself growth hormone. Second: it has a real, documented FDA history that ended for non-clinical reasons. The rest of this site walks through both. ## The FDA record, in one paragraph Two New Drug Applications carry the sermorelin record. The first, NDA 19-863, was approved in 1990 as a diagnostic stimulation agent for pituitary growth hormone reserve [5]. The second, NDA 020443, was approved in 1997 for the long-term treatment of idiopathic growth hormone deficiency in pediatric patients with growth failure [5]. The manufacturer stopped producing the therapeutic formulation in 2008 and the agency formally accepted the withdrawal in 2009 [6]. In 2013, the FDA published a Federal Register determination — the substantive one for current compounding rights — finding that the discontinuation was a commercial decision, not a safety or effectiveness signal [6]. That single regulatory finding is the legal predicate that allows state-licensed Section 503A pharmacies to compound sermorelin on an individual prescription today [12]. ## Why this notebook exists The query "is sermorelin legit" is a defensive search. People typing it want to know whether they are reading about a real peptide with a real history, or a marketing fiction stitched together by a vendor. The honest answer is layered: sermorelin is a real peptide with two prior FDA approvals, no current FDA-approved product on the US market, and a documented place in Section 503A compounding while final agency rulemaking continues [6][12]. None of those facts cancel the others. This site is an independent reading binder. It pulls the primary literature — the 1990s registration-era pediatric trials, the elderly-adult dosing studies from the same decade, a 2012 cognition trial, a 2020 secretagogue review, the FDA's own Federal Register notice, and the agency's current bulks-list posture — and annotates each one in plain language [1][3][4][5][6][8][12][16]. We do not sell anything. We do not run a pharmacy. We do not give medical advice. Everything here is research summary and historical context. ## How to read this notebook The pages are tabbed like a student's revision binder. The Research page is the long read — mechanism, the registration-era pediatric work, the elderly-adult studies, pharmacokinetics, and the cognition trial. The Dosage page collects the dose values from the published record (diagnostic, pediatric, research-context adult) and explains why intermittent dosing is the protocol the literature settled on [9]. The FAQ answers the most common questions readers arrive with — including the legitimacy question, the half-life question, and the 503A question. The References page is the citations binder, linked out to PubMed, PMC, and the Federal Register, so you can read the primary sources yourself. If you only have a minute, the short version is: sermorelin is a 29-residue GHRH analog, it was twice FDA-approved (1990 diagnostic, 1997 pediatric), the manufacturer left the market in 2008 for commercial reasons (FDA confirmed this in 2013), it currently sits in Category 1 of the interim 503A bulks list, and the research literature on it — including pediatric growth, elderly GH/IGF-1 restoration, and one cognition trial — is small but consistent on mechanism and tolerability [1][5][6][16]. --- An annotated reading of the published research — not a clinic, not a pharmacy, not advice.